You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2025

Profile for Spain Patent: 2593469


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Spain Patent: 2593469

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
9,320,714 Feb 3, 2029 Takeda Pharms Usa ACTOPLUS MET metformin hydrochloride; pioglitazone hydrochloride
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Detailed Analysis of Patent ES2593469: Scope, Claims, and Landscape

Last updated: July 30, 2025

Introduction

Patent ES2593469 pertains to a specific pharmaceutical invention, registered within Spain. As part of strategic patent analysis, a comprehensive review of its claims, scope, and positioning within the patent landscape is essential for stakeholders—be it pharmaceutical companies, generic manufacturers, or patent attorneys. This report provides an in-depth examination of the patent’s technical scope, claim structure, and its standing within the existing patent ecosystem.


Patent Overview

  • Patent Number: ES2593469
  • Title: [Typically the patent title specifies the pharmaceutical composition or process; details would be extracted from the official document.]
  • Filing Date: [Insert date based on available data]
  • Publication Date: [Insert date]
  • Priority and Family Context: The patent may be related to international applications or national priority filings, impacting scope and enforceability.

Scope of Patent ES2593469

The scope of a patent primarily hinges on its claims. Broad claims can restrict competitors more effectively, while narrow claims may be easier to design around. The scope also depends on the patent's description and embodiments.

Technical Field and Background

The patent likely addresses a particular pharmaceutical compound, formulation, or manufacturing process. It may target a specific therapeutic use, such as cardiovascular, anti-inflammatory, or antiviral indications. Clarification of this context informs scope interpretation.

Claim Structure Analysis

  • Independent Claims:
    These define the core inventive concept, usually encompassing the active compound, composition, or process.
    • Example: "A pharmaceutical composition comprising [specific active ingredient] in an amount effective to treat [disease]."
  • Dependent Claims:
    These narrow the scope, adding parameters such as specific dosages, formulations, or manufacturing conditions.

Key Features of the Claims

Based on standard structures:

  • Composition Claims:
    Likely claim the specific active ingredient(s) combined with excipients in a defined ratio.
  • Method Claims:
    Could encompass the process of preparing the drug or administering it.
  • Use Claims:
    May specify novel therapeutic applications or indications.

Claim Limitations and Breadth

  • Scope Breadth:
    If the claims broadly cover any composition comprising the active compound, subject to minimal limitations, the patent holds significant coverage.
  • Narrow Claims:
    Specific formulations, methods, or particular forms like salts, isomers, or crystalline forms reduce the scope and may influence enforceability against competitors.

Patent Landscape and Positioning

Existing Patent Environment

The patent landscape for pharmaceuticals often involves multiple patents covering compounds, formulations, delivery systems, and methods of use. To evaluate the positioning of ES2593469:

  • Comparable Patents in Spain and EU:
    A search reveals whether similar compositions or compounds are protected, indicating potential overlaps or freedom-to-operate concerns.
  • Patent Families:
    The presence of family counterparts in the EPO or PCT filings could extend protection internationally.
  • Competitive Landscape:
    Identifying competing patents or applications aids in understanding the innovativeness and strength of ES2593469.

Related Patent Applications and Prior Art

Prior art might include earlier patents, scientific publications, or formulations disclosed publicly before the filing date, which could influence the patent's novelty or inventive step.
Analysis indicates whether the claimed invention involves an inventive step over existing disclosures.

Legal Status and Maintenance

  • Status:
    Confirm whether the patent remains granted, is under opposition, or expired.
  • Duration and Maintenance:
    Ensuring maintaining fees are paid prolongs the patent's enforceability. This affects strategic considerations.

Implications and Strategic Considerations

The patent’s scope directly influences its enforceability and competitive advantage. Broad claims containing novel active molecules and uses can provide formidable market barriers. Conversely, narrow claims or overlapping patents might necessitate designing around strategies or licensing negotiations.


Conclusion

Patent ES2593469 likely claims a specific pharmaceutical composition, formulation, or process with varying degrees of scope. Its strength as an intellectual property asset depends on claim breadth, novelty, inventive step, and positioning within the existing patent landscape. A thorough freedom-to-operate analysis should consider overlapping patents and potential challenges.


Key Takeaways

  • Claim Analysis: Focus on the independent claims to gauge the core inventive scope; dependent claims refine this scope.
  • Patent Strength: Broad, well-supported claims suggest stronger protection; narrow claims may limit enforceability.
  • Landscape Positioning: Competition analysis reveals potential conflicts or opportunities for licensing and partnership.
  • International Strategy: Extension of protections through patent families enhances global market exclusivity.
  • Vigilance: Monitor patent status to inform strategic decisions, including licensing, patent enforcement, or licensing negotiations.

Frequently Asked Questions

  1. What is the primary innovative aspect of ES2593469?
    It likely pertains to a novel pharmaceutical composition or method involving a specific active ingredient or formulation, designed to treat a particular condition with enhanced efficacy or stability.

  2. How broad are the claims in ES2593469?
    Based on available information, the claims may focus on specific compounds, formulations, or uses. Without the full patent text, the breadth can only be estimated, but typically, independent claims define the core invention with potential narrow dependent claims.

  3. Does ES2593469 overlap with existing patents?
    Potential overlaps depend on prior art disclosures and similar patents. A comprehensive patent search should be performed to confirm the novelty and inventive step relative to prior patents in Spain and internationally.

  4. Can competitors design around ES2593469?
    If the claims are narrow, competitors might develop alternative formulations or methods avoiding the specific scope. Broad claims provide more robust protection, making design-arounds more challenging.

  5. What strategic actions should patent holders consider?
    Maintaining patent prosecution, monitoring for potential infringement, exploring licensing opportunities, and expanding protections via patent families are recommended.


References

  1. Official Patent Database: Spanish Patent Office (OEPM), patent ES2593469 documentation.
  2. European Patent Office (EP Register): For related patent filings and family data.
  3. Patent Landscape Reports: For industry-specific patent trends within pharmaceuticals.

(Please note that due to the lack of full patent document access in this context, some details are inferred based on standard patent analysis practices. For a comprehensive assessment, review of the full patent text, claims, and prosecution history is recommended.)

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.